IL2 and neoplasm: There are many tumour-CAF co-targeting clinical trials currently recruiting patients: for example, RO6874281 is a recombinant fusion protein that targets an engineered, variant form of IL-2 to human FAP+ cells, to stimulate a local immune response and therefore improve anti-tumour immunity.